Literature DB >> 19306748

Does incidental irradiation with doses below 50 gy effectively reduce isolated nodal failures in non-small-cell lung cancer: dose-response relationship.

Lucyna Kepka1, Bogusław Maciejewski, Rodney H Withers.   

Abstract

PURPOSE: To evaluate the dose-response relationship for a wide range of doses lower than 50 Gy delivered to the hilar and mediastinal lymph node stations from incidental irradiation in 220 patients with non-small-cell lung cancer (NSCLC) treated with three-dimensional conformal radiotherapy. The endpoint was isolated nodal recurrence (INR) in stations that were initially negative. METHODS AND MATERIALS: The individual responses of 2596 nodal stations were analyzed. Different fractionation schedules were used in different patients. Total prescribed tumor doses ranged from 52 Gy to 74 Gy given over 16-56 days. There were 1198 nodal stations (46%) within and 1398 stations beyond the elective nodal irradiation (ENI) volumes. The INR incidence was estimated for six dose levels ranging from 5 +/- 5 Gy to > or = 56 Gy.
RESULTS: There were a total of 25 INRs in 17 patients (8%). The incidence of INR within the electively treated volumes was 0.58%, compared with 1.28% in nodal stations beyond the ENI. Almost 80% of the INRs occurred during 10 months of follow-up. A strong dose-response relationship was seen for the lower "incidental" doses, most of which were less than 50 Gy. As the dose increased from 5 +/- 5 Gy to 40 +/- 5 Gy, the rate of freedom from INR increased from 12% to 76% (p = 0.005).
CONCLUSIONS: There is evidence of a dose-response relationship between a reduction in the rate of INR and doses lower than 50 Gy. This suggests that incidental irradiation can eradicate at least some subclinical metastases in regional lymph nodes.

Entities:  

Mesh:

Year:  2009        PMID: 19306748     DOI: 10.1016/j.ijrobp.2008.07.070

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.

Authors:  Joe Y Chang; Ritsuko Komaki; Charles Lu; Hong Y Wen; Pamela K Allen; Anne Tsao; Michael Gillin; Radhe Mohan; James D Cox
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

2.  Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Authors:  Aparna H Kesarwala; Christine J Ko; Holly Ning; Eric Xanthopoulos; Karl E Haglund; William P O'Meara; Charles B Simone; Ramesh Rengan
Journal:  Clin Lung Cancer       Date:  2014-12-09       Impact factor: 4.785

3.  Comparison of nodal irradiation dose using radiotherapy for patients with thoracic esophageal cancer.

Authors:  Ni Zhang; Min Gu; Jiahao Wang; Shixiu Wu
Journal:  Oncol Lett       Date:  2019-12-03       Impact factor: 2.967

4.  Protons safely allow coverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer.

Authors:  R C Nichols; S H Huh; B S Hoppe; R H Henderson; Z Li; S Flampouri; H J D'Agostino; J D Cury; D C Pham; N P Mendenhall
Journal:  Technol Cancer Res Treat       Date:  2011-08

5.  Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis.

Authors:  Jochen Fleckenstein; Andrea Eschler; Katharina Kremp; Stephanie Kremp; Christian Rübe
Journal:  Radiat Oncol       Date:  2015-08-21       Impact factor: 3.481

6.  A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.

Authors:  Anurag K Singh; Mark Hennon; Sung Jun Ma; Todd L Demmy; Anthony Picone; Elizabeth U Dexter; Chumy Nwogu; Kristopher Attwood; Wei Tan; Gregory M Hermann; Simon Fung-Kee-Fung; Harish K Malhotra; Sai Yendamuri; Jorge A Gomez-Suescun
Journal:  BMC Cancer       Date:  2018-11-29       Impact factor: 4.430

7.  Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.

Authors:  Daquan Wang; Nan Bi; Tao Zhang; Zongmei Zhou; Zefen Xiao; Jun Liang; Dongfu Chen; Zhouguang Hui; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Jingbo Wang; Chunyu Wang; Xiaotong Lu; Kunpeng Xu; Linfang Wu; Wenji Xue; Qinfu Feng; Luhua Wang
Journal:  Radiat Oncol       Date:  2019-06-13       Impact factor: 3.481

8.  How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions.

Authors:  Rei Umezawa; Yoshinori Ito; Akihisa Wakita; Satoshi Nakamura; Hiroyuki Okamoto; Kana Takahashi; Koji Inaba; Naoya Murakami; Hiroshi Igaki; Keiichi Jingu; Jun Itami
Journal:  Adv Radiat Oncol       Date:  2019-09-13

9.  Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation.

Authors:  Tetsuya Komatsu; Etsuo Kunieda; Tadashi Kitahara; Takeshi Akiba; Ryuta Nagao; Tsuyoshi Fukuzawa
Journal:  J Radiat Res       Date:  2015-11-12       Impact factor: 2.724

Review 10.  Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF).

Authors:  Ruijian Li; Liang Yu; Sixiang Lin; Lina Wang; Xin Dong; Lingxia Yu; Weiyi Li; Baosheng Li
Journal:  Radiat Oncol       Date:  2016-09-21       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.